Free Research Reports on These Drug Makers Stocks -- Novartis, Heron Therapeutics, Aerie Pharma, and Pfizer

Friday, December 1, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Dec. 01, 2017 /PRNewswire/ --

In keeping with the commitment to dynamically provide members with timely

information, has issued free tailored Stock Review on NVS, HRTX, AERI, and PFE which is a click away at has initiated research coverage on four major players in the Drug Manufacturers
space, and they are Novartis AG (NYSE: NVS), Heron Therapeutics Inc. (NASDAQ: HRTX), Aerie Pharmaceuticals Inc. (NASDAQ: AERI), and Pfizer Inc. (NYSE: PFE). Pharmaceutical manufacturers compete to discover and commercialize ever-more effective medicines. Companies focus on the most profitable markets where demand for treatment is high. Free Downloads on Wall St. Equities today, sign up now and access these stocks' research reports at:


Basel, Switzerland headquartered Novartis AG's stock finished Thursday's session 0.76% higher at $85.80 with a total trading volume of 927,676 shares. Over the last month and the previous three months, the Company's shares have advanced 3.90% and 1.79%, respectively. Additionally, the stock has gained 17.79% since the start of this year. Shares of the Company are trading above their 50-day and 200-day moving averages by 1.63% and 5.60%, respectively. Moreover, shares of Novartis, which researches, develops, manufactures, and markets healthcare products worldwide, have a Relative Strength Index (RSI) of 61.02. Free Access to this morning's research report on NVS at:

Heron Therapeutics

Shares in San Diego, California headquartered Heron Therapeutics Inc. rose 3.83%, ending yesterday's session at $17.60. A total volume of 1.30 million shares was traded, which was above their three months average volume of 778,990 shares. The stock has gained 14.66% in the past month, 6.67% in the previous three months, and 34.35% on an YTD basis. The Company's shares are trading 10.26% above their 50-day moving average and 15.93% above their 200-day moving average. Moreover, shares of Heron Therapeutics, which engages in developing medicines to address unmet medical needs, has an RSI of 64.54.

On November 09th, 2017, Heron Therapeutics announced that the US FDA has approved CINVANTI™ (aprepitant) injectable emulsion for intravenous infusion. CINVANTI is a substance P/neurokinin-1 receptor antagonist indicated in adults, in combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin, and nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. Find your free research report HRTX at:

Aerie Pharmaceuticals

On Thursday, Irvine, California-based Aerie Pharmaceuticals Inc.'s stock climbed 3.05%, to close the day at $64.25. A total volume of 325,289 shares was traded. The Company's shares have advanced 4.05% in the last one month, 12.03% in the previous three months, and 69.75% on an YTD basis. The stock is trading 8.19% and 23.24% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Aerie Pharma, which focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases, have an RSI of 63.65.

On November 27th, 2017, Aerie Pharma announced the appointment of Nhi Ong as Director of Analytics, reporting to Gerry McKenzie, Vice President of Commercial Operations. Mr. Ong will be responsible for directing the information and analytics functions in support of the Company's commercial organization. He previously held related positions at Valeant Pharmaceuticals International, Inc. and ThromboGenics.

Sign up today for the free research report on AERI at:


Shares in New York headquartered Pfizer Inc. ended the day 0.14% higher at $36.26. A total volume of 22.18 million shares was traded, which was above their three months average volume of 16.13 million shares. The stock has gained 3.42% in the last one month, 6.90% in the previous three months, and 11.64% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 1.43% and 6.29%, respectively. Furthermore, shares of Pfizer, which discovers, develops, manufactures, and sells healthcare products worldwide, have an RSI of 65.55.

On November 13th, 2017, Pfizer announced that Albert Bourla has been named COO, effective January 01st, 2018. Bourla, 56, has been the Group President of the Company's Innovative Health Business since the beginning of 2016. Under his leadership, revenues for the Innovative Health business grew 11% operationally in 2016 and 9% operationally in the first nine months of 2017. Wall St. Equities' research coverage also includes the downloadable free report on PFE at:

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


View original content:

SOURCE Wall St. Equities

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store